Crossmark

AI-powered design accelerates the development of mRNA therapeutics

Crossref DOI link: https://doi.org/10.1038/s41589-025-02074-0

Published Online: 2025-11-14

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Zhengwei

Dong, Yizhou https://orcid.org/0000-0001-5786-0659
License Information

Text and Data Mining valid from 2025-11-14

Version of Record valid from 2025-11-14
More Information

Article History

First Online: 14 November 2025

Competing interests

: Y.D. is a co-founder and holds equity in Immunanoengineering Therapeutics. Z.L. declares no competing interests.